دورية أكاديمية
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
| العنوان: | Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience |
|---|---|
| المؤلفون: | Galletti C., Ragusa M., Sireci F., Ciodaro F., Barbieri M. A., Giunta G., Grigaliute E., Immordino A., Lorusso F., Dispenza F., Freni F., Galletti F., Gallina S., La Mantia I., Galletti B. |
| المساهمون: | Galletti C., Ragusa M., Sireci F., Ciodaro F., Barbieri M.A., Giunta G., Grigaliute E., Immordino A., Lorusso F., Dispenza F., Freni F., Galletti F., Gallina S., La Mantia I., Galletti B. |
| بيانات النشر: | W.B. Saunders |
| سنة النشر: | 2024 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | CRSwNP, Smell, Dupilumab, ENT, Rhinology |
| الوصف: | Objective: This study aimed to evaluate the effectiveness and safety of dupilumab during the first year of treatment in a real-life setting, focusing on improvement in nasal polyp score (NPS) as well as specific symptoms, quality of life and olfactory function. Methodology/principal: A multicentric observational cohort study was carried out. A total of 170 patients were enrolled in the Otorhinolaryngology Unit of the three University Hospitals and considered for dupilumab therapy. All recorder characteristics were age (at the first dupilumab application visit), sex, smoke habits, previous local and systemic corticosteroid therapy, history of endoscopic sinus surgery, number of previous endoscopic sinus surgery, concomitant asthma, history of an allergic condition, immunoglobulin E (IgE), allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin Exacerbated Respiratory Disease (AERD), other comorbidities associated, blood eosinophils, nasal polyp score, sinonasal outcome test 22 (SNOT 22), sniffin' stick test, the start date of dupilumab therapy and number of doses of dupilumab and eventually, Dupilumab's adverse events related to administration. The Wilcoxon test for dependent samples was performed to compare variables. Statistical significance was assumed for p values < 0.05. Results: A statistically significant reduction in SNOT-22 and NPS was shown at the 6th and 12th month compared to baseline values (p < 0.001 for both comparisons). A statistically significant increase value at the Sniffin' sticks test was shown in the 6th and 12th month compared to baseline values (p < 0.001 for both comparisons). At the 12-month follow-up, according to EUFOREA indications, all patients were considered to remain in treatment with dupilumab and continued the treatment because of a reduced NPS, improved quality of life and a reduced need for system corticosteroids. Dupilumab seemed to be well tolerated by all patients. Any adverse effect of the drug led to the quit of biological treatment. Conclusions: This ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37948824; info:eu-repo/semantics/altIdentifier/wos/WOS:001112115800001; volume:45; issue:1; firstpage:1; lastpage:6; numberofpages:6; journal:AMERICAN JOURNAL OF OTOLARYNGOLOGY; https://hdl.handle.net/10447/620754Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85176255645 |
| DOI: | 10.1016/j.amjoto.2023.104106 |
| الإتاحة: | https://doi.org/10.1016/j.amjoto.2023.104106Test https://hdl.handle.net/10447/620754Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F945C6E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.amjoto.2023.104106 |
|---|